These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20098681)

  • 21. Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting.
    Plissonneau M; Pansieri J; Heinrich-Balard L; Morfin JF; Stransky-Heilkron N; Rivory P; Mowat P; Dumoulin M; Cohen R; Allémann É; Tόth É; Saraiva MJ; Louis C; Tillement O; Forge V; Lux F; Marquette C
    J Nanobiotechnology; 2016 Jul; 14(1):60. PubMed ID: 27455834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.
    Button EB; Boyce GK; Wilkinson A; Stukas S; Hayat A; Fan J; Wadsworth BJ; Robert J; Martens KM; Wellington CL
    Alzheimers Res Ther; 2019 May; 11(1):44. PubMed ID: 31084613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology.
    Rothman SM; Tanis KQ; Gandhi P; Malkov V; Marcus J; Pearson M; Stevens R; Gilliland J; Ware C; Mahadomrongkul V; O'Loughlin E; Zeballos G; Smith R; Howell BJ; Klappenbach J; Kennedy M; Mirescu C
    J Neuroinflammation; 2018 Sep; 15(1):256. PubMed ID: 30189875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TOM1 Regulates Neuronal Accumulation of Amyloid-β Oligomers by FcγRIIb2 Variant in Alzheimer's Disease.
    Gwon Y; Kam TI; Kim SH; Song S; Park H; Lim B; Lee H; Lee W; Jo DG; Jung YK
    J Neurosci; 2018 Oct; 38(42):9001-9018. PubMed ID: 30185465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
    Terai K; Iwai A; Kawabata S; Tasaki Y; Watanabe T; Miyata K; Yamaguchi T
    Neuroscience; 2001; 104(2):299-310. PubMed ID: 11377835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.
    Howlett DR; Bowler K; Soden PE; Riddell D; Davis JB; Richardson JC; Burbidge SA; Gonzalez MI; Irving EA; Lawman A; Miglio G; Dawson EL; Howlett ER; Hussain I
    Histol Histopathol; 2008 Jan; 23(1):67-76. PubMed ID: 17952859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
    Tackenberg C; Kulic L; Nitsch RM
    PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.
    Casas C; Sergeant N; Itier JM; Blanchard V; Wirths O; van der Kolk N; Vingtdeux V; van de Steeg E; Ret G; Canton T; Drobecq H; Clark A; Bonici B; Delacourte A; Benavides J; Schmitz C; Tremp G; Bayer TA; Benoit P; Pradier L
    Am J Pathol; 2004 Oct; 165(4):1289-300. PubMed ID: 15466394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery.
    Omtri RS; Davidson MW; Arumugam B; Poduslo JF; Kandimalla KK
    Mol Pharm; 2012 Jul; 9(7):1887-97. PubMed ID: 22574751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease.
    Zhang H; Zhang L; Zhou D; He X; Wang D; Pan H; Zhang X; Mei Y; Qian Q; Zheng T; Jones FE; Sun B
    Neurobiol Dis; 2017 Oct; 106():171-180. PubMed ID: 28684271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo.
    Lee EB; Zhang B; Liu K; Greenbaum EA; Doms RW; Trojanowski JQ; Lee VM
    J Cell Biol; 2005 Jan; 168(2):291-302. PubMed ID: 15642747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuronal activity regulates the regional vulnerability to amyloid-β deposition.
    Bero AW; Yan P; Roh JH; Cirrito JR; Stewart FR; Raichle ME; Lee JM; Holtzman DM
    Nat Neurosci; 2011 Jun; 14(6):750-6. PubMed ID: 21532579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease.
    Lorenzo A; Yuan M; Zhang Z; Paganetti PA; Sturchler-Pierrat C; Staufenbiel M; Mautino J; Vigo FS; Sommer B; Yankner BA
    Nat Neurosci; 2000 May; 3(5):460-4. PubMed ID: 10769385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease.
    Maloney MT; Minamide LS; Kinley AW; Boyle JA; Bamburg JR
    J Neurosci; 2005 Dec; 25(49):11313-21. PubMed ID: 16339026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice.
    Lazarov O; Lee M; Peterson DA; Sisodia SS
    J Neurosci; 2002 Nov; 22(22):9785-93. PubMed ID: 12427834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats.
    Wilson EN; Do Carmo S; Welikovitch LA; Hall H; Aguilar LF; Foret MK; Iulita MF; Jia DT; Marks AR; Allard S; Emmerson JT; Ducatenzeiler A; Cuello AC
    J Alzheimers Dis; 2020; 73(2):723-739. PubMed ID: 31868669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
    Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
    Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.
    Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A
    Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.